organization · Reporting owner
Pacira BioSciences, Inc.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TELA Bio, Inc.TELA · Entity 7381 | Director · 10% owner | November 13, 2019 | November 14, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TELA Bio, Inc.
Report date November 13, 2019 · Filed November 14, 2019
Jointly reported with Ellis Ronald J. Jr.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Pacira BioSciences, Inc. | 774,056 |
Reported balance
After 2019-11-13 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-11-13 · Conversion · Acquired 580,357 · Balance 774,056 F1: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F2: Reflects 193,699 shares of common stock received as a payment-in-kind dividend on Series B Preferred Stock exempt from reporting under Rule 16a-9(a). |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Pacira BioSciences, Inc. | 0 |
Reported balance
After 2019-11-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-11-13 · Conversion · Disposed 14,329,052 · Balance 0 F1: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F3: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
F2: Reflects 193,699 shares of common stock received as a payment-in-kind dividend on Series B Preferred Stock exempt from reporting under Rule 16a-9(a).
F3: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 13, 2019 Filed Nov 14, 2019 02:06 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionSeries B Preferred Stock · Derivative | 14,329,052 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000432 · edgar.xml · derivative · entry 2 Ellis Ronald J. Jr. · CIK 0001790670 · Director · 10% owner Pacira BioSciences, Inc. · CIK 0001396814 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pacira BioSciences, Inc. Disclosed balance after: 0 Underlying: Common Stock · 580,357 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F3 · derivative.underlying_shares: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 02:06 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionCommon Stock | 580,357 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-19-000432 · edgar.xml · nonDerivative · entry 1 Ellis Ronald J. Jr. · CIK 0001790670 · Director · 10% owner Pacira BioSciences, Inc. · CIK 0001396814 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pacira BioSciences, Inc. Disclosed balance after: 774,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F2 · balance_after: Reflects 193,699 shares of common stock received as a payment-in-kind dividend on Series B Preferred Stock exempt from reporting under Rule 16a-9(a). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.